治療腎細胞癌聯合療法申請獲受理 和黃醫藥(00013.HK)現升近5% 信達生物(01801.HK)倒跌
和黃醫藥(00013.HK)與信達生物(01801.HK)聯合公佈,旗下(口夫)(口奎)替尼(fruquintinib)和信迪利單抗(sintilimab)用於治療既往接受過一種酪氨酸激(酉每)抑制劑治療失敗的局部晚期或轉移性的腎細胞癌患者的聯合療法,其新藥上市申請已獲中國國家藥監局受理。
和黃醫藥今早高開2.53%,最高見25.1元。現報24.85元,升4.85%,成交262.3萬股,涉資6,492.28萬元。昨日已炒高的信達生物今早平開,最低見71.8元。現報72.1元,跌2.9%,成交447.99萬股,涉資3.26億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.